Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

241. Interventions for raising breast cancer awareness in women.

Interventions for raising breast cancer awareness in women. BACKGROUND: Breast cancer continues to be the most commonly diagnosed cancer in women globally. Early detection, diagnosis and treatment of breast cancer are key to better outcomes. Since many women will discover a breast cancer symptom themselves, it is important that they are breast cancer aware i.e. have the knowledge, skills and confidence to detect breast changes and present promptly to a healthcare professional. OBJECTIVES (...) : To assess the effectiveness of interventions for raising breast cancer awareness in women. SEARCH METHODS: We searched the Cochrane Breast Cancer Group's Specialised Register (searched 25 January 2016), Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 12) in the Cochrane Library (searched 27 January 2016), MEDLINE OvidSP (2008 to 27 January 2016), Embase (Embase.com, 2008 to 27 January 2016), the World Health Organization's International Clinical Trials Registry Platform (ICTRP

Cochrane2017

242. Knowledge and Attitudes About Breast Cancer in Limpopo, South Africa

Knowledge and Attitudes About Breast Cancer in Limpopo, South Africa 29094090 2018 11 13 2378-9506 3 5 2017 Oct Journal of global oncology J Glob Oncol Knowledge and Attitudes About Breast Cancer in Limpopo, South Africa. 509-514 10.1200/JGO.2016.008102 Breast cancer survival is unacceptably low in many low-resource settings, including rural South Africa, where access to screening and treatment services is limited. To describe the context for implementing an early detection program, we assessed (...) knowledge and attitudes toward breast cancer risk, early detection, and treatment. We conducted a cross-sectional survey among 243 women presenting to Hlokomela Clinic in Hoedspruit, South Africa, during April and May 2016. We used quantitative and qualitative analyses to determine levels of knowledge of risk factors, symptoms, and treatment of breast cancer, as well as experience with and attitudes toward detection and treatment methods. Thirty-one percent of women correctly identified at least six

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

243. Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular

Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular 29244990 2018 07 19 2018 11 13 2378-9506 3 6 2017 Dec Journal of global oncology J Glob Oncol Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular. 757-764 10.1200/JGO.2016.007377 Purpose One half of the Mexican population lacks comprehensive health care coverage. In 2003, a reform to the General Health Law was approved that led to the creation of the System (...) of Social Protection in Health and made universal health coverage mandatory. The main innovation of this reform was Seguro Popular, which provided coverage for breast cancer. Here we report the outcomes of women with breast cancer treated at a cancer center in Mexico under Seguro Popular. Materials and Methods This was a retrospective cohort study that included all patients with breast cancer treated in the Instituto Nacional de Cancerología in Mexico City between January 2007 and December 2013

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

244. Genetic testing and counseling among patients with newly diagnosed breast cancer

Genetic testing and counseling among patients with newly diagnosed breast cancer 28170472 2017 02 10 2018 12 02 1538-3598 317 5 2017 02 07 JAMA JAMA Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer . 531-534 10.1001/jama.2016.16918 Kurian Allison W AW Stanford University, Department of Medicine, Stanford, California. Griffith Kent A KA University of Michigan, Department of Biostatistics, Ann Arbor. Hamilton Ann S AS University of Southern California, Department (...) United States 5NU58DP003862 CC CDC HHS United States P01 CA163233 CA NCI NIH HHS United States U58 DP003875 DP NCCDPHP CDC HHS United States HHSN261201300015C RC CCR NIH HHS United States HHSN261201000035I CA NCI NIH HHS United States HHSN261201000034C CA NCI NIH HHS United States U58 DP003862 DP NCCDPHP CDC HHS United States Letter Comment United States JAMA 7501160 0098-7484 AIM IM JAMA Oncol. 2015 Jun;1(3):277-8 26181167 Breast Neoplasms diagnosis Counseling Genes, BRCA1 Genes, BRCA2 Genetic

JAMA2017 Full Text: Link to full Text with Trip Pro

245. Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer 28740920 2018 11 13 2452-1094 2 2 2017 Apr-Jun Advances in radiation oncology Adv Radiat Oncol Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer. 105-109 10.1016/j.adro.2017.01.012 Our goal was to determine the impact of pathologic response after neoadjuvant chemotherapy in triple negative (...) breast cancer (TNBC) on the subsequent risk of locoregional recurrence (LRR) and disease-free survival (DFS) in the setting of adjuvant radiation therapy. This was an institutional review board-approved retrospective chart review of patients with clinical stage I-III breast cancer treated with neoadjuvant chemotherapy, local surgery (breast conservation or mastectomy), and adjuvant radiation therapy between 1997 and 2015. Medical records were reviewed for clinical stage, tumor grade and subtype

Advances in radiation oncology2017 Full Text: Link to full Text with Trip Pro

246. Oncotype DX DCIS breast cancer test (Genomic Health Inc.)

Oncotype DX DCIS breast cancer test (Genomic Health Inc.) Oncotype DX DCIS breast cancer test (Genomic Health Inc.) Oncotype DX DCIS breast cancer test (Genomic Health Inc.) HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Oncotype DX DCIS breast cancer test (Genomic Health Inc.) Lansdale: HAYES, Inc. Genetic Testing Publication. 2016 (...) Authors' objectives Ductal carcinoma in situ (DCIS), commonly referred to as stage 0 breast cancer, is defined as neoplastic proliferation of epithelial cells that are confined to the mammary ductal-lobular system. Advancements in routine screening mammography have seen a substantial increase in the number of DCIS cases diagnosed each year, yet the prognosis for a woman diagnosed with DCIS is not well defined. Current recommended treatment guidelines for DCIS include lumpectomy plus radiation, total

Health Technology Assessment (HTA) Database.2017

247. Brachytherapy as an adjunct to other types of radiation therapy for breast cancer

Brachytherapy as an adjunct to other types of radiation therapy for breast cancer Brachytherapy as an adjunct to other types of radiation therapy for breast cancer Brachytherapy as an adjunct to other types of radiation therapy for breast cancer HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Brachytherapy as an adjunct to other types (...) of radiation therapy for breast cancer. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' objectives Brachytherapy involves temporary implantation of radioactive materials at the site of a tumor. For treatment of breast cancer, brachytherapy is generally performed after breast-conserving surgery such as lumpectomy, either in the form of accelerated partial breast irradiation, the sole type of radiation, or as a radiation boost in combination with a standard course of whole-breast radiation

Health Technology Assessment (HTA) Database.2017

248. Accelerated partial breast irradiation for breast cancer using conformal and intensity-modulated radiation therapy

Accelerated partial breast irradiation for breast cancer using conformal and intensity-modulated radiation therapy Accelerated partial breast irradiation for breast cancer using conformal and intensity-modulated radiation therapy Accelerated partial breast irradiation for breast cancer using conformal and intensity-modulated radiation therapy HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation HAYES, Inc.. Accelerated partial breast irradiation for breast cancer using conformal and intensity-modulated radiation therapy . Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' objectives Following breast-conserving surgery in patients with early-stage breast cancer, accelerated partial breast irradiation (APBI) is an alternative to standard whole-breast irradiation (WBI) performed to reduce the risk of tumor recurrence. APBI using 3-dimensional

Health Technology Assessment (HTA) Database.2017

249. Accelerated partial breast irradiation for breast cancer using brachytherapy

Accelerated partial breast irradiation for breast cancer using brachytherapy Accelerated partial breast irradiation for breast cancer using brachytherapy Accelerated partial breast irradiation for breast cancer using brachytherapy HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Accelerated partial breast irradiation for breast cancer (...) using brachytherapy. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' objectives Brachytherapy involves temporary implantation of radioactive materials at the site of a tumor. For treatment of breast cancer, brachytherapy is generally performed after lumpectomy. The goal of this procedure, which may be performed as an adjunct to chemotherapy or hormonotherapy, is to irradiate and destroy any residual tumor cells while sparing normal breast tissue and preserving cosmetic appearance

Health Technology Assessment (HTA) Database.2017

250. Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer

Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Loading Loading A A A Evidence to Improve Care Share: Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening (...) in Women at Less Than High Risk for Breast Cancer Ontario Health Technology Advisory Committee Recommendation The Ontario Health Technology Advisory Committee recommends against publicly funding screening breast magnetic resonance imaging (MRI) as an adjunct to screening mammography for women who are at less than high risk for breast cancer and who have no personal history of breast cancer Breast cancer is the most common cancer among Canadian women. The most common form of screening for breast cancer

Health Quality Ontario2017

253. [Invitation and decision guide for breast cancer screening]

[Invitation and decision guide for breast cancer screening] Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0 [Invitation and decision guide for breast cancer screening] Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0 [Invitation and decision guide for breast cancer screening] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0. [Invitation and decision guide for breast cancer screening] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG

Health Technology Assessment (HTA) Database.2017

254. [Circulating tumour cells in breast cancer: clinical use of the CellSearch© test]

[Circulating tumour cells in breast cancer: clinical use of the CellSearch© test] Cellules tumorales circulantes dans les cas de cancer du sein : utilisation clinique du test CellSearch® [Circulating tumour cells in breast cancer: clinical use of the CellSearch® test] Cellules tumorales circulantes dans les cas de cancer du sein : utilisation clinique du test CellSearch® [Circulating tumour cells in breast cancer: clinical use of the CellSearch® test] Le Blanc R Citation Le Blanc R. Cellules (...) tumorales circulantes dans les cas de cancer du sein : utilisation clinique du test CellSearch®. [Circulating tumour cells in breast cancer: clinical use of the CellSearch® test] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). Note informative. 2016 Authors' conclusions Based on the scientific literature identified, the use of CellSearch® tests as a predictive and prognostic biomarker in patients with early-stage breast cancer is not justified. The evidence

Health Technology Assessment (HTA) Database.2017

255. [Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer]

[Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer] Biomarkerbasierte tests zur entscheidung für oder gegen eine adjuvante systemische chemotherapie beim primären mammakarzinom; abschlussbericht; auftrag D14-01 [Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer] Biomarkerbasierte tests zur entscheidung für oder gegen eine adjuvante systemische chemotherapie beim primären (...) mammakarzinom; abschlussbericht; auftrag D14-01 [Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG

Health Technology Assessment (HTA) Database.2017

256. [Aromatase inhibitors in female breast cancer]

[Aromatase inhibitors in female breast cancer] Aromatasehemmer beim mammakarzinom der frau: abschlussbericht; auftrag A10-0 [Aromatase inhibitors in female breast cancer] Aromatasehemmer beim mammakarzinom der frau: abschlussbericht; auftrag A10-0 [Aromatase inhibitors in female breast cancer] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Aromatasehemmer beim mammakarzinom der frau: abschlussbericht; auftrag A10-0. [Aromatase inhibitors in female breast cancer] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 437. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Aromatase; Aromatase Inhibitors; Breast Neoplasms

Health Technology Assessment (HTA) Database.2017

257. Salute to the sun: a new dawn in yoga therapy for breast cancer

Salute to the sun: a new dawn in yoga therapy for breast cancer 28134483 2018 04 30 2018 12 02 2051-3909 64 3 2017 Sep Journal of medical radiation sciences J Med Radiat Sci Salute to the sun: a new dawn in yoga therapy for breast cancer. 232-238 10.1002/jmrs.218 Interest in the application of yoga for health benefits in western medicine is growing rapidly, with a significant rise in publications. The purpose of this systematic review is to determine whether the inclusion of yoga therapy (...) to the treatment of breast cancer can improve the patient's physical and psychosocial quality of life (QoL). A search of peer reviewed journal articles published between January 2009 and July 2014 was conducted. Studies were included if they had more than 15 study participants, included interventions such as mindfulness-based stress reduction (MBSR) or yoga therapy with or without comparison groups and had stated physical or psychological outcomes. Screening identified 38 appropriate articles. The most

Journal of medical radiation sciences2017 Full Text: Link to full Text with Trip Pro

258. Disparities in contralateral prophylactic mastectomy use among women with early-stage breast cancer

Disparities in contralateral prophylactic mastectomy use among women with early-stage breast cancer 28649642 2018 11 13 2374-4677 3 2017 NPJ breast cancer NPJ Breast Cancer Disparities in contralateral prophylactic mastectomy use among women with early-stage breast cancer. 2 10.1038/s41523-017-0004-z Contralateral prophylactic mastectomy use has increased over the past decades among women with early-stage breast cancer. Racial differences in contralateral prophylactic mastectomy use are well (...) described, but with unclear causes. This study examined contralateral prophylactic mastectomy use among black and white women and the contribution of differences in perceived risk to differences in use. We surveyed women diagnosed with early-stage unilateral breast cancer between ages 41-64 in Pennsylvania and Florida between 2007-2009 to collect data on breast cancer treatment, family history, education, income, insurance, and perceived risk. Clinical factors-age,stage at diagnosis, receptor status

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

259. Inhibition of the proteasome β2 site sensitizes triple-negative breast cancer cells to β5 inhibitors through a mechanism involving Nrf1 suppression

Inhibition of the proteasome β2 site sensitizes triple-negative breast cancer cells to β5 inhibitors through a mechanism involving Nrf1 suppression 28132893 2017 11 16 2018 11 13 2451-9448 24 2 2017 Feb 16 Cell chemical biology Cell Chem Biol Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation. 218-230 S2451-9456(16)30477-9 10.1016/j.chembiol.2016.12.016 The proteasome inhibitors carfilzomib (Cfz) and bortezomib (...) (Btz) are used successfully to treat multiple myeloma, but have not shown clinical efficacy in solid tumors. Here we show that clinically achievable inhibition of the β5 site of the proteasome by Cfz and Btz does not result in loss of viability of triple-negative breast cancer cell lines. We use site-specific inhibitors and CRISPR-mediated genetic inactivation of β1 and β2 to demonstrate that inhibiting a second site of the proteasome, particularly the β2 site, sensitizes cell lines to Btz and Cfz

Cell chemical biology2017 Full Text: Link to full Text with Trip Pro

260. Developing a Breast Cancer Screening Program in Nigeria: Evaluating Current Practices, Perceptions, and Possible Barriers

Developing a Breast Cancer Screening Program in Nigeria: Evaluating Current Practices, Perceptions, and Possible Barriers 29094087 2018 11 13 2378-9506 3 5 2017 Oct Journal of global oncology J Glob Oncol Developing a Breast Cancer Screening Program in Nigeria: Evaluating Current Practices, Perceptions, and Possible Barriers. 490-496 10.1200/JGO.2016.007641 In low- and middle-income countries like Nigeria, women present with advanced breast cancer at an earlier age. Given the limited resources (...) , development of screening programs that parallel resource capabilities of low- and middle-income countries is imperative. The objective of this study was to evaluate the perceptions, practices, and barriers regarding clinical breast examination (CBE) screening in a low-income community in Nigeria. A cross-sectional survey of women age 40 years or older in Ife, Nigeria, using multistaged sampling was performed. Information on sociodemographics, knowledge of breast cancer, screening practices

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro